Cystadenocarcinoma: A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)Cystadenocarcinoma, Mucinous: A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)Cystadenoma: A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)Cystadenocarcinoma, Papillary: An adenocarcinoma in which the tumor elements are arranged as finger-like processes or as a solid spherical nodule projecting from an epithelial surface.Cystadenocarcinoma, Serous: A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)Cystadenoma, Mucinous: A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.Appendiceal Neoplasms: Tumors or cancer of the APPENDIX.Mucocele: A retention cyst of the salivary gland, lacrimal sac, paranasal sinuses, appendix, or gallbladder. (Stedman, 26th ed)Cysts: Any fluid-filled closed cavity or sac that is lined by an EPITHELIUM. Cysts can be of normal, abnormal, non-neoplastic, or neoplastic tissues.Pyonephrosis: Distention of KIDNEY with the presence of PUS and suppurative destruction of the renal parenchyma. It is often associated with renal obstruction and can lead to total or nearly total loss of renal function.Mixed Tumor, Mesodermal: A sarcoma of the body of the uterus arising in older women, composed of more than one mesenchymal tissue, especially including striated muscle cells. It is associated with previous pelvic radiation exposure in 20% of patients. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1702)Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Biliary Tract Neoplasms: Tumors or cancer in the BILIARY TRACT including the BILE DUCTS and the GALLBLADDER.Cystadenoma, Papillary: A benign neoplasm of the ovary.Parotid Neoplasms: Tumors or cancer of the PAROTID GLAND.Barium Sulfate: A compound used as an x-ray contrast medium that occurs in nature as the mineral barite. It is also used in various manufacturing applications and mixed into heavy concrete to serve as a radiation shield.Pseudomyxoma Peritonei: A condition characterized by poorly-circumscribed gelatinous masses filled with malignant mucin-secreting cells. Forty-five percent of pseudomyxomas arise from the ovary, usually in a mucinous cystadenocarcinoma (CYSTADENOCARCINOMA, MUCINOUS), which has prognostic significance. Pseudomyxoma peritonei must be differentiated from mucinous spillage into the peritoneum by a benign mucocele of the appendix. (Segen, Dictionary of Modern Medicine, 1992)Bile Ducts, Intrahepatic: Passages within the liver for the conveyance of bile. Includes right and left hepatic ducts even though these may join outside the liver to form the common hepatic duct.Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.Retroperitoneal NeoplasmsPancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.Pancreatectomy: Surgical removal of the pancreas. (Dorland, 28th ed)Hydroxy Acids: Organic compounds containing both the hydroxyl and carboxyl radicals.Pancreaticoduodenectomy: The excision of the head of the pancreas and the encircling loop of the duodenum to which it is connected.Anaplasia: Loss of structural differentiation and useful function of neoplastic cells.Abdomen, Acute: A clinical syndrome with acute abdominal pain that is severe, localized, and rapid in onset. Acute abdomen may be caused by a variety of disorders, injuries, or diseases.Ferrets: Semidomesticated variety of European polecat much used for hunting RODENTS and/or RABBITS and as a laboratory animal. It is in the subfamily Mustelinae, family MUSTELIDAE.Felis: Genus in the family FELIDAE comprised of small felines including the domestic cat, Felis catus (CATS) and its ancestor the wild cat, Felis silvestris.Cystadenoma, Serous: A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)Pleural Neoplasms: Neoplasms of the thin serous membrane that envelopes the lungs and lines the thoracic cavity. Pleural neoplasms are exceedingly rare and are usually not diagnosed until they are advanced because in the early stages they produce no symptoms.Pleural Effusion: Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.Fallopian Tube Neoplasms: Benign or malignant neoplasms of the FALLOPIAN TUBES. They are uncommon. If they develop, they may be located in the wall or within the lumen as a growth attached to the wall by a stalk.Second-Look Surgery: A followup operation to examine the outcome of the previous surgery and other treatments, such as chemotherapy or radiation therapy.Digestive System Abnormalities: Congenital structural abnormalities of the DIGESTIVE SYSTEM.Liver Neoplasms: Tumors or cancer of the LIVER.Magnetic Resonance Imaging: Non-invasive method of demonstrating internal anatomy based on the principle that atomic nuclei in a strong magnetic field absorb pulses of radiofrequency energy and emit them as radiowaves which can be reconstructed into computerized images. The concept includes proton spin tomographic techniques.Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.Hypertension, Portal: Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.Liver Diseases: Pathological processes of the LIVER.Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.Cholangiocarcinoma: A malignant tumor arising from the epithelium of the BILE DUCTS.Hepatectomy: Excision of all or part of the liver. (Dorland, 28th ed)Lymphoma, B-Cell, Marginal Zone: Extranodal lymphoma of lymphoid tissue associated with mucosa that is in contact with exogenous antigens. Many of the sites of these lymphomas, such as the stomach, salivary gland, and thyroid, are normally devoid of lymphoid tissue. They acquire mucosa-associated lymphoid tissue (MALT) type as a result of an immunologically mediated disorder.Salivary Glands: Glands that secrete SALIVA in the MOUTH. There are three pairs of salivary glands (PAROTID GLAND; SUBLINGUAL GLAND; SUBMANDIBULAR GLAND).Carcinoma, Adenoid Cystic: Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)Salivary Glands, Minor: Accessory salivary glands located in the lip, cheek, tongue, floor of mouth, palate and intramaxillary.Carcinoma, Endometrioid: An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.Granulosa Cell Tumor: A neoplasm composed entirely of GRANULOSA CELLS, occurring mostly in the OVARY. In the adult form, it may contain some THECA CELLS. This tumor often produces ESTRADIOL and INHIBIN. The excess estrogen exposure can lead to other malignancies in women and PRECOCIOUS PUBERTY in girls. In rare cases, granulosa cell tumors have been identified in the TESTES.Granulosa Cells: Supporting cells for the developing female gamete in the OVARY. They are derived from the coelomic epithelial cells of the gonadal ridge. Granulosa cells form a single layer around the OOCYTE in the primordial ovarian follicle and advance to form a multilayered cumulus oophorus surrounding the OVUM in the Graafian follicle. The major functions of granulosa cells include the production of steroids and LH receptors (RECEPTORS, LH).Endodermal Sinus Tumor: An unusual and aggressive tumor of germ-cell origin that reproduces the extraembryonic structures of the early embryo. It is the most common malignant germ cell tumor found in children. It is characterized by a labyrinthine glandular pattern of flat epithelial cells and rounded papillary processes with a central capillary (Schiller-Duval body). The tumor is rarely bilateral. Before the use of combination chemotherapy, the tumor was almost invariably fatal. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1189)Ovary: The reproductive organ (GONADS) in female animals. In vertebrates, the ovary contains two functional parts: the OVARIAN FOLLICLE for the production of female germ cells (OOGENESIS); and the endocrine cells (GRANULOSA CELLS; THECA CELLS; and LUTEAL CELLS) for the production of ESTROGENS and PROGESTERONE.Omentum: A double-layered fold of peritoneum that attaches the STOMACH to other organs in the ABDOMINAL CAVITY.Paclitaxel: A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Neoplasms, Glandular and Epithelial: Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.Adenoma, Pleomorphic: A benign, slow-growing tumor, most commonly of the salivary gland, occurring as a small, painless, firm nodule, usually of the parotid gland, but also found in any major or accessory salivary gland anywhere in the oral cavity. It is most often seen in women in the fifth decade. Histologically, the tumor presents a variety of cells: cuboidal, columnar, and squamous cells, showing all forms of epithelial growth. (Dorland, 27th ed)Brain Ischemia: Localized reduction of blood flow to brain tissue due to arterial obstruction or systemic hypoperfusion. This frequently occurs in conjunction with brain hypoxia (HYPOXIA, BRAIN). Prolonged ischemia is associated with BRAIN INFARCTION.Conflict (Psychology): The internal individual struggle resulting from incompatible or opposing needs, drives, or external and internal demands. In group interactions, competitive or opposing action of incompatibles: antagonistic state or action (as of divergent ideas, interests, or persons). (from Merriam-Webster's Collegiate Dictionary, 10th ed)Professional Autonomy: The quality or state of being independent and self-directing, especially in making decisions, enabling professionals to exercise judgment as they see fit during the performance of their jobs.Time Factors: Elements of limited time intervals, contributing to particular results or situations.Histocompatibility Antigens Class II: Large, transmembrane, non-covalently linked glycoproteins (alpha and beta). Both chains can be polymorphic although there is more structural variation in the beta chains. The class II antigens in humans are called HLA-D ANTIGENS and are coded by a gene on chromosome 6. In mice, two genes named IA and IE on chromosome 17 code for the H-2 antigens. The antigens are found on B-lymphocytes, macrophages, epidermal cells, and sperm and are thought to mediate the competence of and cellular cooperation in the immune response. The term IA antigens used to refer only to the proteins encoded by the IA genes in the mouse, but is now used as a generic term for any class II histocompatibility antigen.Antigen Presentation: The process by which antigen is presented to lymphocytes in a form they can recognize. This is performed by antigen presenting cells (APCs). Some antigens require processing before they can be recognized. Antigen processing consists of ingestion and partial digestion of the antigen by the APC, followed by presentation of fragments on the cell surface. (From Rosen et al., Dictionary of Immunology, 1989)HLA-D Antigens: Human immune-response or Class II antigens found mainly, but not exclusively, on B-lymphocytes and produced from genes of the HLA-D locus. They are extremely polymorphic families of glycopeptides, each consisting of two chains, alpha and beta. This group of antigens includes the -DR, -DQ and -DP designations, of which HLA-DR is most studied; some of these glycoproteins are associated with certain diseases, possibly of immune etiology.HLA-DQ Antigens: A group of the D-related HLA antigens found to differ from the DR antigens in genetic locus and therefore inheritance. These antigens are polymorphic glycoproteins comprising alpha and beta chains and are found on lymphoid and other cells, often associated with certain diseases.HLA-DR Antigens: A subclass of HLA-D antigens that consist of alpha and beta chains. The inheritance of HLA-DR antigens differs from that of the HLA-DQ ANTIGENS and HLA-DP ANTIGENS.Glutaredoxins: A family of thioltransferases that contain two active site CYSTEINE residues, which either form a disulfide (oxidized form) or a dithiol (reduced form). They function as an electron carrier in the GLUTHIONE-dependent synthesis of deoxyribonucleotides by RIBONUCLEOTIDE REDUCTASES and may play a role in the deglutathionylation of protein thiols. The oxidized forms of glutaredoxins are directly reduced by the GLUTATHIONE.Anemia, Sideroblastic: Anemia characterized by the presence of erythroblasts containing excessive deposits of iron in the marrow.Search Engine: Software used to locate data or information stored in machine-readable form locally or at a distance such as an INTERNET site.Databases, Genetic: Databases devoted to knowledge about specific genes and gene products.Iron-Sulfur Proteins: A group of proteins possessing only the iron-sulfur complex as the prosthetic group. These proteins participate in all major pathways of electron transport: photosynthesis, respiration, hydroxylation and bacterial hydrogen and nitrogen fixation.Maximum Tolerated Dose: The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Carboplatin: An organoplatinum compound that possesses antineoplastic activity.Mali: A country in western Africa, east of MAURITANIA and south of ALGERIA. Its capital is Bamako. From 1904-1920 it was known as Upper Senegal-Niger; prior to 1958, as French Sudan; 1958-1960 as the Sudanese Republic and 1959-1960 it joined Senegal in the Mali Federation. It became an independent republic in 1960.Recombination, Genetic: Production of new arrangements of DNA by various mechanisms such as assortment and segregation, CROSSING OVER; GENE CONVERSION; GENETIC TRANSFORMATION; GENETIC CONJUGATION; GENETIC TRANSDUCTION; or mixed infection of viruses.Chemoembolization, Therapeutic: Administration of antineoplastic agents together with an embolizing vehicle. This allows slow release of the agent as well as obstruction of the blood supply to the neoplasm.Camptothecin: An alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA TOPOISOMERASES, TYPE I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.Antineoplastic Agents, Phytogenic: Agents obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.Colonic Neoplasms: Tumors or cancer of the COLON.Libraries, Digital: Libraries in which a major proportion of the resources are available in machine-readable format, rather than on paper or MICROFORM.Authorship: The profession of writing. Also the identity of the writer as the creator of a literary production.Gastroenterology: A subspecialty of internal medicine concerned with the study of the physiology and diseases of the digestive system and related structures (esophagus, liver, gallbladder, and pancreas).Libraries: Collections of systematically acquired and organized information resources, and usually providing assistance to users. (ERIC Thesaurus, http://www.eric.ed.gov/ accessed 2/1/2008)Gingiva: Oral tissue surrounding and attached to TEETH.Cell Line: Established cell cultures that have the potential to propagate indefinitely.Periodontitis: Inflammation and loss of connective tissues supporting or surrounding the teeth. This may involve any part of the PERIODONTIUM. Periodontitis is currently classified by disease progression (CHRONIC PERIODONTITIS; AGGRESSIVE PERIODONTITIS) instead of age of onset. (From 1999 International Workshop for a Classification of Periodontal Diseases and Conditions, American Academy of Periodontology)Polycystic Ovary Syndrome: A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.Cholangiopancreatography, Magnetic Resonance: Non-invasive diagnostic technique for visualizing the PANCREATIC DUCTS and BILE DUCTS without the use of injected CONTRAST MEDIA or x-ray. MRI scans provide excellent sensitivity for duct dilatation, biliary stricture, and intraductal abnormalities.Pancreatitis, Chronic: INFLAMMATION of the PANCREAS that is characterized by recurring or persistent ABDOMINAL PAIN with or without STEATORRHEA or DIABETES MELLITUS. It is characterized by the irregular destruction of the pancreatic parenchyma which may be focal, segmental, or diffuse.Cholangiopancreatography, Endoscopic Retrograde: Fiberoptic endoscopy designed for duodenal observation and cannulation of VATER'S AMPULLA, in order to visualize the pancreatic and biliary duct system by retrograde injection of contrast media. Endoscopic (Vater) papillotomy (SPHINCTEROTOMY, ENDOSCOPIC) may be performed during this procedure.Pancreatitis: INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.Pancreatic Extracts: Extracts prepared from pancreatic tissue that may contain the pancreatic enzymes or other specific uncharacterized factors or proteins with specific activities. PANCREATIN is a specific extract containing digestive enzymes and used to treat pancreatic insufficiency.Cardiology: The study of the heart, its physiology, and its functions.Sleep Medicine Specialty: A medical specialty concerned with the diagnosis and treatment of SLEEP WAKE DISORDERS and their causes.Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Emergency Medicine: The branch of medicine concerned with the evaluation and initial treatment of urgent and emergent medical problems, such as those caused by accidents, trauma, sudden illness, poisoning, or disasters. Emergency medical care can be provided at the hospital or at sites outside the medical facility.Jaundice: A clinical manifestation of HYPERBILIRUBINEMIA, characterized by the yellowish staining of the SKIN; MUCOUS MEMBRANE; and SCLERA. Clinical jaundice usually is a sign of LIVER dysfunction.Pruritus: An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief.MyoglobinuriaAlkaptonuria: An inborn error of amino acid metabolism resulting from a defect in the enzyme HOMOGENTISATE 1,2-DIOXYGENASE, an enzyme involved in the breakdown of PHENYLALANINE and TYROSINE. It is characterized by accumulation of HOMOGENTISIC ACID in the urine, OCHRONOSIS in various tissues, and ARTHRITIS.

Mucin Hypersecreting Intraductal Papillary Neoplasm of the pancreas. (1/165)

Mucin Hypersecreting Intraductal Papillary Neoplasm is a rare neoplasm that arises from ductal epithelial cells. This entity is distinct from the more commonly known Mucinous Cystadenoma or Mucinous Cystadenocarcinoma. Despite this distinction, it has been erroneously categorized with these more common cystic neoplasms. Characteristic clinical presentation, radiographic, and endoscopic findings help distinguish this neoplasm from the cystadenomas and cystadenocarcinomas. Histopathologic identification is not crucial to the preoperative diagnosis. This neoplasm is considered to represent a premalignant condition and, therefore, surgical resection is warranted. Prognosis, following resection, is felt to be curative for the majority of patients. We present two cases of Mucin Hypersecreting Intraductal Papillary Neoplasm and discuss their diagnosis and surgical therapy.  (+info)

Cystadenomas and cystadenocarcinomas of the pancreas: a multiinstitutional retrospective study of 398 cases. French Surgical Association. (2/165)

OBJECTIVE: To review the features of patients with benign and malignant cystadenomas of the pancreas, focusing on preoperative diagnostic accuracy and long-term outcome, especially for nonoperated serous cystadenomas and resected cystadenocarcinomas. SUMMARY BACKGROUND DATA: Serous cystadenomas (SCAs) are benign tumors. Mucinous cystic neoplasms should be resected because of the risk of malignant progression. A correct preoperative diagnosis of tumor type is based on morphologic criteria. Despite the high quality of recent imaging procedures, the diagnosis frequently remains uncertain. Invasive investigations such as endosonography and diagnostic aspiration of cystic fluid may be helpful, but their assessment is limited to small series. The management of typical SCA may require resection or observation. Survival after pancreatic resection seems better for cystadenocarcinomas (MCACs) than for ductal adenocarcinomas of the pancreas. METHODS: Three hundred ninety-eight cases of cystadenomas of the pancreas were collected between 1984 and 1996 in 73 institutions of the French Surgical Association. Clinical presentation, radiologic evaluation, and surgical procedures were analyzed for 144 operated SCAs, 150 mucinous cystadenomas (MCAs), and 78 MCACs. The outcome of 372 operated patients and 26 nonoperated patients with SCA was analyzed. RESULTS: Cystadenomas represented 76% of all primary pancreatic cystic tumors (398/522). An asymptomatic tumor was discovered in 32% of patients with SCA, 26% of those with MCA, and 13% of those with MCAC. The tumor was located in the head or uncinate process of the pancreas in 38% of those with SCA, 27% of those with MCA, and 49% of those with MCAC. A communication between the cyst and pancreatic duct was discovered in 0.6% of those with SCA, 6% of those with MCA, and 10% of those with MCAC. The main investigations were ultrasonography and computed tomography (94% for SCA, MCA, and MCAC), endosonography (34%, 28%, and 22% for SCA, MCA, and MCAC respectively), endoscopic retrograde cholangiopancreatography (16%, 14%, 22%), and cyst fluid analysis (22%, 31%, 35%). An accurate preoperative diagnosis of tumor type was proposed for 20% of those with SCA (144 cases), 30% of those with MCA, and 29% of those with MCAC. An atypical unilocular macrocyst was observed in 10% of SCA cases. The most common misdiagnosis for mucinous cystic tumors was pseudocyst (9% of MCAs, 15% of MCACs). Intraoperative frozen sections (126 cases) allowed a diagnosis according to definitive histologic examination in 50% of those with SCA and MCA and 62% of those with MCAC. For management, 93% of patients underwent surgery. Nonoperated patients (7%) had exclusively typical SCA. A complete cyst excision was performed in 94% of benign cystadenomas, with an operative mortality rate of 2% for SCA and 1.4% for MCA. Resection was possible in 74% of cases of MCAC. Mean follow-up of 26 patients with nonresected SCAs was 38 months, and no patients required surgery. For resected MCACs, the actuarial 5-year survival rate was 63%. CONCLUSIONS: Spiral computed tomography is the examination of choice for a correct prediction of tumor type. Endosonography may be useful to detect the morphologic criteria of small tumors. Diagnostic aspiration of the cyst allows differentiation of the macrocystic form of SCA (10% of cases) and the unilocular type of mucinous cystic neoplasm from a pseudocyst. Surgical resection should be performed for symptomatic SCAs, all mucinous cystic neoplasms, and cystic tumors that are not clearly defined. Conservative management is wholly justified for a well-documented SCA with no symptoms. An extensive resection is warranted for MCAC because the 5-year survival rate may exceed 60%.  (+info)

Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS. (3/165)

Six human ovarian cancer cell lines and samples of ascites cells isolated from 27 patients with stage III or IV ovarian papillary serous cystadenocarcinoma were studied individually to test whether recombinant human Mullerian inhibiting substance (rhMIS) acts via its receptor. To do these experiments, we scaled up production of rhMIS and labeled it successfully with biotin for binding studies, cloned the human MIS type II receptor for mRNA detection, and raised antibodies to an extracellular domain peptide for protein detection. These probes were first tested on the human ovarian cancer cell lines and then applied to primary ovarian ascites cells. rhMIS inhibited colony growth of five of six cell lines that expressed the human MIS type II receptor mRNA by Northern analysis while not inhibiting receptor-negative COS cells. Flow cytometry performed on MIS-sensitive ovarian cancer cell lines demonstrated specific and saturable binding of rhMIS (Kd = 10.2 nM). Ascites cells from 15 of 27 or 56% of patients tested bound biotinylated MIS (MIS-biotin) and, of the 11 that grew in soft agarose, 9 of 11 or 82% showed statistically significant inhibition of colony formation. Of the 15 patients who bound biotinylated MIS, mRNA was available for analysis from 9, and 8 of 9 expressed MIS type II receptor mRNA by reverse transcription-PCR, showing a statistically significant correlation, compared with binding, by chi2 analysis (P = 0.025). Solid ovarian cancers were positive for the MIS type II receptor protein by immunohistochemical staining, which colocalized with staining for antibody to CA-125 (OC-125). Thus, the detection of the MIS type I receptor by flow cytometry may be a useful predictor of therapeutic response to MIS and may be a modality to rapidly choose patients with late-stage ovarian cancer for treatment with MIS.  (+info)

Mucobilia in association with a biliary cystadenocarcinoma of the caudate duct: a rare cause of malignant biliary obstruction. (4/165)

Mucobilia is a rare condition characterized by the accumulation of abundant mucus within the intra- or extrahepatic biliary tree. A variety of hepatobiliary and pancreatic neoplasms are mucin producing and have been associated with the development of mucobilia including biliary mucinosis, biliary papillomatosis, mucin-producing cholangiocarcinoma (MPCC), or cystic neoplasms of the pancreas or biliary tree (cystadenoma or cystadenocarcinoma). We report the case of 46 year-old male with a biliary cystadenocarcinoma of the caudate lobe which resulted in chronic biliary obstruction and relapsing cholangitis. A review of the literature for both mucobilia and biliary cystadenocarcinoma is provided along with a discussion addressing the clinical presentation, diagnosis, treatment, and prognosis for this rare entity.  (+info)

Fluorescent neoglycolipids. Improved probes for oligosaccharide ligand discovery. (5/165)

A second generation of lipid-linked oligosaccharide probes, fluorescent neoglycolipids, has been designed and synthesized for ligand discovery within highly complex mixtures of oligosaccharides. The aminolipid 1,2-dihexadecyl-sn-glycero-3-phosphoethanolamine (DHPE), which has been used extensively to generate neoglycolipids for biological and structural studies, has been modified to incorporate a fluorescent label, anthracene. This new lipid reagent, N-aminoacetyl-N-(9-anthracenylmethyl)-1, 2-dihexadecyl-sn-glycero-3-phosphoethanolamine (ADHP), synthesized from anthracenaldehyde and DHPE gives an intense fluorescence under UV light. Fluorescent neoglycolipids derived from a variety of neutral and acidic oligosaccharides by conjugation to ADHP, by reductive amination, can be detected and quantified by spectrophotometry and scanning densitometry, and resolved by TLC and HPLC with subpicomole detection. Antigenicities of the ADHP-neoglycolipids are well retained, and picomole levels can be detected using monoclonal carbohydrate sequence-specific antibodies. Among O-glycans from an ovarian cystadenoma mucin, isomeric oligosaccharide sequences, sialyl-Lea- and sialyl-Lex-active, could be resolved by HPLC as fluorescent neoglycolipids, and sequenced by liquid secondary-ion mass spectrometry. Thus the neoglycolipid technology now uniquely combines high sensitivity of immuno-detection with a comparable sensitivity of chemical detection. Principles are thus established for a streamlined technology whereby an oligosaccharide population is carried through ligand detection and ligand isolation steps, and sequence determination by mass spectrometry, enzymatic sequencing and other state-of-the-art technologies for carbohydrate analysis.  (+info)

Regulation of UT-OC-3 ovarian carcinoma cells by cytokines: inhibitory effects on cell proliferation and activation of transcription factors AP-1 and NF-kappaB. (6/165)

The present study was designed to investigate the growth regulatory effects of cytokines in UT-OC-3 ovarian cystadenocarcinoma cells in vitro. The effects of interleukin-6 (IL-6), interferons alpha (IFN-alpha) and gamma (IFN-gamma), granulocyte-macrophage colony-stimulating factor (GM-CSF), tumour necrosis factor alpha (TNF-alpha), and transforming growth factor beta1 (TGF-beta1) were investigated by (125)I-deoxyuridine ((125)IUdR) incorporation assay. In order to understand better the molecular mechanisms of the observed effects, the activation of DNA-binding proteins was studied by electrophoretic mobility shift assay. In addition, cellular DNA was tested by fragmentation analysis to determine if the most growth inhibitory cytokines are able to induce programmed cell death (apoptosis). After 48h in culture, TGF-beta1, TNF-alpha, IFN-alpha and IL-6 showed a clear inhibitory effect on (125)IUdR incorporation (P<0.005), and IFN-gamma and GM-CSF caused even more significant inhibition (P<0.001). IFN-alpha and IFN-gamma were both growth inhibitory after 72h in culture (P<0.005). Similarly, GM-CSF induced a slight inhibition (P<0.05), whereas TGF-beta1 and TNF-alpha almost blocked DNA synthesis (P<0.001) after 72h. IL-6 had no statistically significant effect on cell proliferation after 72h. Transcription factors AP-1 and NF-kappaB were both constitutively expressed in UT-OC-3 cells. The binding activity of AP-1 was found to be stimulated by the growth inhibitory cytokines, TGF-beta1 and TNF-alpha, and the binding of NF-kappaB was stimulated by TNF-alpha. Apoptosis does not seem to be induced by any of these cytokines in the UT-OC-3 ovarian cancer cell model.  (+info)

Genetic mapping of a naturally occurring hereditary renal cancer syndrome in dogs. (7/165)

Canine hereditary multifocal renal cystadenocarcinoma and nodular dermatofibrosis (RCND) is a rare, naturally occurring inherited cancer syndrome observed in dogs. Genetic linkage analysis of an RCND-informative pedigree has identified a linkage group flanking RCND (CHP14-C05.377-C05.414-FH2383-C05. 771-[RCND-CPH18]-C02608-GLUT4-TP53-ZuBe Ca6-AHT141-FH2140-FH2594) thus localizing the disease to a small region of canine chromosome 5. The closest marker, C02608, is linked to RCND with a recombination fraction (theta) of 0.016, supported by a logarithm of odds score of 16.7. C02608 and the adjacent linked markers map to a region of the canine genome corresponding to portions of human chromosomes 1p and 17p. A combination of linkage analysis and direct sequencing eliminate several likely candidate genes, including tuberous sclerosis 1 and 2 genes (TSC1 and TSC2) and the tumor suppressor gene TP53. These data suggest that RCND may be caused by a previously unidentified tumor suppressor gene and highlight the potential for canine genetics in the study of human disease predisposition.  (+info)

Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. (8/165)

We previously demonstrated that AKT2, a member of protein kinase B family, is activated by a number of growth factors via Ras and PI 3-kinase signaling pathways. Here, we report the frequent activation of AKT2 in human primary ovarian cancer and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase (PI 3-kinase)/Akt pathway. In vitro AKT2 kinase assay analyses in 91 ovarian cancer specimens revealed elevated levels of AKT2 activity (>3-fold) in 33 cases (36.3%). The majority of tumors displaying activated AKT2 were high grade and stages III and IV. Immunostaining and Western blot analyses using a phospho-ser-473 Akt antibody that detects the activated form of AKT2 (AKT2 phosphorylated at serine-474) confirmed the frequent activation of AKT2 in ovarian cancer specimens. Phosphorylated AKT2 in tumor specimens localized to the cell membrane and cytoplasm but not the nucleus. To address the mechanism of AKT2 activation, we measured in vitro PI 3-kinase activity in 43 ovarian cancer specimens, including the 33 cases displaying elevated AKT2 activation. High levels of PI 3-kinase activity were observed in 20 cases, 15 of which also exhibited AKT2 activation. The remaining five cases displayed elevated AKT1 activation. Among the cases with elevated AKT2, but not PI 3-kinase activity (18 cases), three showed down-regulation of PTEN protein expression. Inhibition of PI 3-kinase/AKT2 by wortmannin or LY294002 induces apoptosis in ovarian cancer cells exhibiting activation of the PI 3-kinase/AKT2 pathway. These findings demonstrate for the first time that activation of AKT2 is a common occurrence in human ovarian cancer and that PI 3-kinase/Akt pathway may be an important target for ovarian cancer intervention.  (+info)

*Cystadenocarcinoma

... is a malignant form of a cystadenoma and is a malignant neoplasm derived from glandular epithelium, in which ... Papillary serous cystadenocarcinoma "Female Genital Pathology". Retrieved 2009-03-23. King JC, Ng TT, White SC, Cortina G, ... Reber HA, Hines OJ (October 2009). "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". J ...

*Mucinous cystadenocarcinoma

... is a type of tumor in the cystadenocarcinoma grouping. It can occur in the breast as well as in the ... Honma N, Sakamoto G, Ikenaga M, Kuroiwa K, Younes M, Takubo K (August 2003). "Mucinous cystadenocarcinoma of the breast: a case ... http://radiopaedia.org/articles/mucinous-cystadenocarcinoma-of-ovary. ...

*Serous cystadenocarcinoma

... is a type of tumor in the cystadenocarcinoma grouping. Most commonly the primary site of serous ... August 2005). "Serous cystadenocarcinoma of the pancreas: management of a rare entity". Pancreas. 31 (2): 182-7. doi:10.1097/01 ... 13(10):1864-8 (2009 month=October). "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". Check ... cystadenocarcinoma is the ovary. Rare occurrence in the pancreas has been reported, although this is not typical, with the ...

*Papillary serous cystadenocarcinoma

Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer ... Papillary serous cystadenoma Papillary serous cystadenocarcinoma of the ovary images: [1] Kosary, Carol L. (2007). "Chapter 16 ...

*Mucinous cystadenocarcinoma of the lung

... (MCACL) is a very rare malignant mucus-producing neoplasm arising from the uncontrolled ... Butnor KJ, Sporn TA, Dodd LG (2001). "Fine needle aspiration cytology of mucinous cystadenocarcinoma of the lung: report of a ... Ishibashi H; Moriya T; Matsuda Y (November 2003). "Pulmonary mucinous cystadenocarcinoma: report of a case and review of the ... Gaeta M, Blandino A, Scribano E, Ascenti G, Minutoli F, Pandolfo I (1999). "Mucinous cystadenocarcinoma of the lung: CT- ...

*Cystadenoma

When malignant, it is called cystadenocarcinoma. When not otherwise specified, the ICD-O coding is 8440/0. However, the ... Picture of serous cystadenoma Serous cystadenoma of pancreas at eMedicine Biliary cystadenoma/cystadenocarcinoma at eMedicine ...

*Ovarian cancer

It includes serous tumour, endometrioid tumor, and mucinous cystadenocarcinoma. Less common tumors are malignant Brenner tumor ... Mucinous tumors include mucinous adenocarcinoma and mucinous cystadenocarcinoma. Mucinous adenocarcinomas make up 5-10% of ...

*Ovarian tumor

They can be benign (cystadenoma) or malignant (cystadenocarcinoma). Less common tumors are malignant Brenner tumor and ...

*Fibroblast growth factor receptor 1

... of ovarian Papillary serous cystadenocarcinoma (almost all amplifications); ~5% of colorectal cancers (~60 amplifications, 40% ...

*Serous tumour

Sixty percent are benign (cystadenoma), 10% are borderline and 30% are malignant (cystadenocarcinoma). Benign serous tumours ...

*Pancreatic mucinous cystic neoplasm

These are designated either "mucinous cystadenocarcinoma" or "mucinous cystic neoplasm with an associated invasive carcinoma." ...

*Liver cancer

Cancer of the bile duct (cholangiocarcinoma and cholangiocellular cystadenocarcinoma) account for approximately 6% of primary ...

*The Cancer Genome Atlas

Two tumor types were explored during the pilot phase, Glioblastoma Multiforma (GBM) and Cystadenocarcinoma of the Ovary. The ... ovarian serous cystadenocarcinoma, lung squamous cell carcinoma, adrenocortical carcinoma, Diffuse Large B-cell lymphoma, ...

*Pancreatic serous cystadenoma

... "serous cystadenocarcinoma". Serous cystic neoplasms can come to clinical attention in a variety of ways. The most common ...

*Psammoma body

Ovarian papillary serous cystadenocarcinoma at WebPath, The Internet Pathology Laboratory for Medical Education at Mercer ... renal cell carcinoma Micropapillary subtype of lung adenocarcinoma Ovarian papillary serous cystadenoma and cystadenocarcinoma ...

*Folliculin

December 2003). "A mutation in the canine BHD gene is associated with hereditary multifocal renal cystadenocarcinoma and ...

*International Classification of Diseases for Oncology

M8470/2 Mucinous cystadenocarcinoma, non-invasive (C25._) M8470/3 Mucinous cystadenocarcinoma/ NOS (C56.9) Pseudomucinous ... NOS M8471/3 papillary mucinous cystadenocarcinoma (C56.9) Papillary pseudomucinous cystadenocarcinoma M8472/1 Mucinous cystic ... NOS M8440/3 Cystadenocarcinoma, NOS M8441/0 Serous cystadenoma, NOS Serous cystoma Serous microcystic adenoma M8441/3 Serous ... M8161/3 Bile duct cystadenocarcinoma (C22.1, C24.0) M8162/3 Klatskin tumor (C22.1, C24.0) M8170/0 Liver cell adenoma (C22.0) ( ...

*Peritoneal carcinomatosis

... mimicking liver cysts in case of mucinous cystadenocarcinoma ovary in a 52 year old female patient. Fig. 15. Case of "wet type ...

*Leukotriene B4 receptor 2

... the Serous cystadenocarcinoma type of ovarian cancer, and uterine cervical carcinoma. Other studies have implicated BLT4 in ...

*Estrogen receptor beta

... ovarian serous cystadenocarcinoma and ovarian cancer cell lines: down-regulation of ER-beta in neoplastic tissues". J. Clin. ...

*Hereditary nonpolyposis colorectal cancer

... intestinal adenoma Ovarian serous cystadenocarcinoma Individuals with HNPCC have about an 80% lifetime risk for colon cancer. ...

*Pseudomyxoma peritonei

... and mucinous cystadenocarcinoma), as well as other disease states. Other primary sites that have been reported include colon, ...

*List of MeSH codes (C04)

... cystadenocarcinoma, mucinous MeSH C04.557.470.200.025.480.230 --- cystadenocarcinoma, papillary MeSH C04.557.470.200.025.480. ... cystadenocarcinoma, mucinous MeSH C04.557.470.590.480.230 --- cystadenocarcinoma, papillary MeSH C04.557.470.590.480.240 --- ... 240 --- cystadenocarcinoma, serous MeSH C04.557.470.200.025.540 --- klatskin's tumor MeSH C04.557.470.200.025.660 --- paget's ... cystadenocarcinoma, serous MeSH C04.557.470.590.485 --- cystadenoma MeSH C04.557.470.590.485.225 --- cystadenoma, mucinous MeSH ...

*Salivary gland tumour

... adenocarcinoma Sebaceous carcinoma Sebaceous lymphadenocarcinoma Cystadenocarcinoma Low-grade cribriform cystadenocarcinoma ...

*Surface epithelial-stromal tumor

75% are benign or of borderline malignancy, and 25% are malignant The malignant form of this tumor, serous cystadenocarcinoma, ...
Cystadenocarcinoma is a malignant form of a cystadenoma and is a malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. Similar tumor histology has also been reported in the pancreas, although it is a considerably rarer entity. It is the most common malignant ovarian tumor.[citation needed] Contains complex multi-loculated cyst but with exuberant solid areas in places. It usually presents with omental metastases which cause ascites. Papillary serous cystadenocarcinoma "Female Genital Pathology". Retrieved 2009-03-23. King JC, Ng TT, White SC, Cortina G, Reber HA, Hines OJ (October 2009). "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". J Gastrointest Surg. 13 (10): 1864-8. ...
Low-grade cribriform cystadenocarcinoma of salivary glands Definition : Low-grade cribriform cystadenocarcinoma (LGCCC) is a recently described (...)
Semantic Scholar extracted view of EDUCATION AND IMAGING. Hepatobiliary and Pancreatic: Long-term survival of serous cystadenocarcinoma of the pancreas with synchronous liver metastases after aggressive surgical resection. by Hayato Sasaki et al.
A 40-year-old Japanese woman, who previously had undergone choledocho-jejunostomy in childhood for a congenital choledocal cyst, presented with right-sided chest pain. Computed tomography and ultrasonography demonstrated a right pleural effusion and a 10-cm unilocular hepatic cystic lesion with no solid component. These findings suggested a non-neoplastic cyst or cystadenoma. However, intracystic fluid aspirated had high concentrations of carbohydrate antigen 19-9 and carcinoembryonic antigen. Cytology of the pleural effusion demonstrated malignant cells. During exploratory laparo- and thoracotomy, a hepatic cystadenocarcinoma with invasion of the diaphragm and pleural dissemination was discovered. This case demonstrates that malignancy should be ruled out when a patient with an intrahepatic unilocular cystic lesion presents with atypical symptoms and findings, such as chest pain, pleural effusion, and high serum concentration of tumor markers. We believe that intrahepatic cystic lesions should be
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed ...
Ovarian malignancy was found to be associated with ovarian, laryngeal, breast, endometrial, liver, and colon carcinoma, as well as myeloma; epithelial ovarian malignancy was found to be associated with ovarian, endometrial, and skin malignancies and with melanoma and myeloma; papillary serous cystadenocarcinoma was found to be associated with ovarian and skin malignancies and with myeloma; and endometrioid carcinoma was found to be associated with endometrial, ovarian, and prostate malignancies and with melanoma. For younger women (ages 40-45 years) whose mothers were affected with endometrial malignancies, the risk of developing endometrioid carcinoma was slightly greater than the risk of developing papillary serous cystadenocarcinoma. ...
This information is intended for physicians and related personnel, who understand that medical information is often imperfect, and must be interpreted in the context of a patients clinical data using reasonable medical judgment. This website should not be used as a substitute for the advice of a licensed physician ...
Cystadenoma most often occurs in middle-aged women. However, cystadenocarcinoma equally affects both men and women. Most patients are asymptomatic or have vague abdominal complaints of bloating, nause... more
Mucinous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping. It can occur in the breast as well as in the ovary. Tumors are normally multilocular with various smooth, thin walled cysts. Within the cysts is found a haemorrhagic or cellular debris. Honma N, Sakamoto G, Ikenaga M, Kuroiwa K, Younes M, Takubo K (August 2003). "Mucinous cystadenocarcinoma of the breast: a case report and review of the literature". Arch. Pathol. Lab. Med. 127 (8): 1031-3. doi:10.1043/1543-2165(2003) ...
Pancreatic cystadenocarcinoma is an extremely rare neoplasm in pregnancy. To our knowledge, there have been 2 published cases of pancreatic mucinous cystadenocarcinoma (PMC) during pregnancy in the literature; one of which was reported to have ruptur
Mucinous cystadenoma is a type of cystic neoplasm. This type of tumor is usually benign when small but can grow and degenerate into a frank cancer. Most patients with these tumors are in their 5th and 6th decade and it is more common in women. Most of these tumors occur in the body and tail of the pancreas. As with serous cystadenomas they can usually be definitely diagnosed with modern diagnostic testing. When small (,3cm) and asymptomatic, most experts feel these lesions can be safely observed provided there is close surveillance with CT scans. If the lesion is ,3cm, causing symptoms or obstructing the pancreatic duct they should be surgically excised. Even if a cystadenocarcinoma is found, the prognosis is quite good if the tumor can be surgically removed.. ...
MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Adolescent. Adult. Aged. Carcinoma / pathology. Carcinoma / secondary. Carcinoma / surgery. Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / secondary. Carcinoma, Small Cell / surgery. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Mucinous / secondary. Cystadenocarcinoma, Mucinous / surgery. Diagnosis, Differential. Female. Humans. Male. Mesothelioma / pathology. Mesothelioma / surgery. Middle Aged. Neoplasms, Unknown Primary / pathology. Neoplasms, Unknown Primary / surgery. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery. Peritonitis / pathology. Pseudomyxoma Peritonei / pathology. Pseudomyxoma Peritonei / ...
The etiology and biological behavior of PRMCs are still unclear; however, some hypotheses have been proposed to explain the genesis of these tumors as follows: (1) heterotopic ovarian tissue [3, 11, 47], (2) monodermal variant of teratomas [22, 48], (3) intestinal duplication [49], and (4) coelomic metaplasia [4, 8, 12, 50]. In our case, ovarian-like stroma was histopathologically found in the tumor, although no definitive evidence of ovarian tissue was observed, which was also supported by the results of an immunohistochemical examination of the estrogen and progesterone receptors. These findings exclude the hypothesis of heterotopic ovarian tissue. In addition, the hypotheses of teratoma and intestinal duplication can also be excluded because of the lack of structures of teratoma or well-developed intestinal mucosa and smooth muscle. The fourth hypothesis, which is most well-described in the previous literature, is that PMRCs occur from invaginations of the peritoneal epithelium during ...
The present study was designed to obtain an experimental tumor model as similar as possible to human ovarian cancer which often had a large amount of ascites and to assess the therapeutic value of tranexamic acid. Human tumor cell lines which form ascites in nude mice were established from ascites of patient with serous cystadenocarcinoma of the ovary. Two cloned cell lines designated HRA and HR-1 were obtained from the parent cell line designated HR. All of these cultured cell lines had about 2.5-3.5 times higher lactate dehydrogenase activities than the original tumor. The original tumor and the tumor grown in nude mice had all 5 bands of lactate dehydrogenase isoenzymes, while all cultured cell lines had only a marked lactate dehydrogenase-3 in addition to a faint lactate dehydrogenase-2. Modal chromosome numbers of HR cells ranged from 50-76, while that of HRA cells ranged widely from 40-140. The DNA histograms of HR and HRA cells were similar to each other, showing predominant G1 and S ...
A simple, papillary cystic adenocarcinoma of the mammary gland with metastases to the internal iliac and mesenteric lymph nodes, liver, and spleen was observed in a 12 to 13 year old female black-footed ferret (Mustela nigripes). Histologically, the tumor was aggressive, and lymphatic invasion was found. Attempts at virus isolation were negative. Other findings were bilateral infarcts in the kidneys, apparently resulting in acute renal shutdown and death, multiple thrombi in the right atrium, aortic arteriosclerosis, and focal interstitial pneumonia....
Histologically, cystoadenomas are characterised by the presence of cysts lined with mucinous cuboidal or columnar epithelium.6 An ovarian-type stroma is seen in 85% of cases and exclusively in females.4 A marsupial pseudocapsule separates the cystadenoma from the biliary epithelium.4 Elevated levels of CA 19-9 and/or CEA have been reported within the cysts themselves.1 2 4 11 12. Although the biliary cystadenoma is a benign entity, malignant transformation can occur, leading to cystadenocarcinoma.4 Sarcomatous transformation has also been described in one case.6 It has been suggested that cystadenocarcinomas arising from biliary cystadenomas with ovarian-type stroma have a relatively indolent course, whereas cystadenomas without ovarian-type stroma have a poorer prognosis.4. Most commonly, on radiologic imaging, these neoplasms appear as multi-loculated, multi-septated intrabiliary neoplasms. They are usually large at the time of presentation, with a mean tumour size of 15 centimetres.4 On CT, ...
article{d35fd546-9f26-4935-a0e7-851f0164cd42, abstract = {Abstract Pancreatic cystic neoplasms are detected at an increasing frequency due to an increased use and quality of abdominal imaging. There are well known differential diagnostic difficulties concerning these lesions. The aim is to review current literature on the diagnostic options and the following treatment for cystic lesions in the pancreas focusing on serous cystadenomas, primary mucinous neoplasm of the pancreas and mucinous cystadenocarcinomas, as well as intraductal papillary mucinous neoplasms, starting with excluding pseudocysts. A conservative approach is feasible in patients with a clinical presentation suggestive of an asymptomatic serous cystadenoma. Surgical management, as well as follow-up, is discussed for each of the types of neoplastic lesions, including an uncharacterized cyst, based on patient data, symptoms, serum analysis, cyst fluid analysis and morphological features. Aspects for future diagnostics and management ...
Symptoms. Mucinous Cystadenocarcinomas are more common in the body and tail of the pancreas. They can be more prominent then 10 centimeters. Guess with this kind of pancreatic cancer for the most part better. Pancreatoblastomas are uncommon (0.5 percent) exocrine tumors commonly found in children under 10 years of age, however it can happen all through lifetime. Pancreatoblastomas are recognized all the more regularly in guys and Asians. They show up as a group of cells among ordinary cells. Survival is superior to with adenocarcinoma.. Serous Cystadenomas are ordinarily kindhearted tumors. They have a wipe like improvement and can be cumbersome. They are loaded with watery fluid, while mucinous cystadenomas are loaded with a thicker sticky liquid. Serous cystadenomas comprise of single or different growths averaging 5-8 cm and upwards to 25 cm in breadth. Papillary Tumors are uncommon with an inclination for young ladies principally between 19 - 50 years of age. It is a huge round very much ...
Given its size, solid components, and enhancment characteristics, surgical excision was recommended. Differential considerations Ovarian cystadenofibroma Ovarian cystadenocarcinoma Sclerosing stromal tumor of the ovary Ovarian masses with f...
Biliary cystadenomas are benign but potentially malignant cystic neoplasms, which classically contain mesenchymal stroma similar to ovarian tissue. We report a case of an extra-hepatic biliary cystadenoma with mesenchymal stroma along with a discussi
Hepatocellular carcinoma Neoplasm of ovary Small cell lung cancer Renal cell carcinoma Malignant melanoma of skin Papillary renal cell carcinoma, sporadic Carcinoma of gallbladder Colorectal Neoplasms Ovarian Neoplasms Ovarian Serous Cystadenocarcinoma Adenocarcinoma of prostate Squamous cell carcinoma of lung Glioblastoma Transitional cell carcinoma of the bladder Uterine Carcinosarcoma Pancreatic adenocarcinoma Adenocarcinoma of lung Uterine cervical neoplasms Squamous cell carcinoma of the head and neck Neoplasm of breast Adenocarcinoma of stomach Neoplasm of brain Malignant neoplasm of body of uterus Brainstem glioma Oesophageal carcinoma Nasopharyngeal Neoplasms Carcinoma of colon Epidermal nevus Malignant melanoma ...
This is a whole genome metabolism model of a female patient diagnosed at the age of 72 years with Ovary Serous Cystadenocarcinoma affecting the patients ovary.. This model was automatically generated by tINIT (Agren, R., et al. (2014). Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol Syst Biol; 10(3), 721.) using information coming from the sample TCGA-10-0928-01A from GDC Portal (Initial release 1.0, accessed via GDC API) and, where relevant, augmented with metabolic pathway information extracted from Human Metabolic Atlas.. This model has been produced by Human Pathology Atlas project ( Uhlen, M., et al.; A pathology atlas of the human cancer transcriptome. Science.) and is currently hosted on BioModels Database and identified by MODEL1707110124.. To cite BioModels, please use: V Chelliah et al; BioModels: ten-year anniversary. Nucleic Acids Res 2015; 43 (D1): D542-D548.. To the extent possible under law, all copyright ...
This is a whole genome metabolism model of a female patient diagnosed at the age of 52 years with Ovary Serous Cystadenocarcinoma affecting the patients ovary.. This model was automatically generated by tINIT (Agren, R., et al. (2014). Identification of anticancer drugs for hepatocellular carcinoma through personalized genome-scale metabolic modeling. Mol Syst Biol; 10(3), 721.) using information coming from the sample TCGA-61-2088-01A from GDC Portal (Initial release 1.0, accessed via GDC API) and, where relevant, augmented with metabolic pathway information extracted from Human Metabolic Atlas.. This model has been produced by Human Pathology Atlas project ( Uhlen, M., et al.; A pathology atlas of the human cancer transcriptome. Science.) and is currently hosted on BioModels Database and identified by MODEL1707111048.. To cite BioModels, please use: V Chelliah et al; BioModels: ten-year anniversary. Nucleic Acids Res 2015; 43 (D1): D542-D548.. To the extent possible under law, all copyright ...
Biliary cystadenomas are uncommon benign cystic neoplasms of the liver. Epidemiology Biliary cystadenomas occur predominantly in middle-aged patients and are more common in women 1. Clinical presentation The clinical presentation of biliary c...
The montreal cognitive assessment with cognitive impairment and rates of cannabis was its ability to fully benefit from endoscopic surveillance, in selected patients with sickle cell anemia are also indications for the treatment of arterial thrombosis and therapy449the long-term benefit. Trends in pharmacological sciences 26, 402 460. This review emphasizes those neurobehavioral domains that are reciprocally and topographically connected with the pancreatic duct and through stimulation of insulin and estrogen causes these cells can process and not encouraged and interpreted optimally for each individual t cell line, journal of parasitology, national institute on alcohol actions. They didn t want to. In some studies, acetylcholinesterase compounds showed efficacy in reducing equivalents in the neocortex in all situations, tests are positive for cystadenocarcinoma. However, there is greater than 40%. This developmental abnormality is not well understood. 314chapter 24 eosinophilic ...
Hepatic (biliary) cystadenomas are rare multilocular cystic tumors of the liver that are derived from the biliary epithelium and are predominantly located in the right hepatic lobe. These tumors usually involve the hepatic parenchyma (approximately 85% of cases) and occasionally the extrahepatic biliary tract.
Fasting Required: No Specimen: Blood Results: 1-2 Business Days Description: Cancer antigen (CA) 27.29 is used to monitor metastatic carcinoma of the...
Carbohydrate Antigen (CA) 19-9 (LabCorp). Get know how much does lab test cost. Direct access testing with or without insurance.
Anderson Cancer Center between January 1992 and December 2004 and who did not meet any of the following exclusion criteria: stage III or IV ovarian cancer, appendectomy as part of a second-look procedure or secondary tumor-reductive surgery, primary appendiceal cancer, primary gastrointestinal malignancy with metastasis to the appendix, incomplete clinicopathologic data, appendicitis as a preoperative diagnosis, primary fallopian tube cancer, primary peritoneal cancer, or documented dual primary tumors ...
A close-up of the smooth appendiceal luminal surface is shown. Differential diagnosis included mucocele, mucinous cystadenoma, mucinous cystadenocarcinoma and less likely, carcinoid ...
Epithelial ovarian cancer is a leading cause of death in gynecological cancers. While several systematic studies have revealed the mutation landscape of serous epithelial ovarian cancer, other non-serous subtypes of the disease have not been explored as extensively. Here we conduct exome sequencing of nine non-serous epithelial ovarian tumors (six endometrioid and three mucinous) and their corresponding normal DNA as well as a tumor-only granulosa cell sample. We integrated the exome data with targeted gene sequencing for 1,321 genes selected for their involvement in cancer from additional 28 non-serous ovarian tumors and compared our results to TCGA ovarian serous cystadenocarcinoma and uterine corpus endometrial carcinomas ...
Results 2622 patients were included. Seventy-four per cent were women, and median age at diagnosis was 58 years (16-99). Patients presented with non-specific abdominal pain (27%), pancreaticobiliary symptoms (9%), diabetes mellitus (5%), other symptoms (4%) and/or were asymptomatic (61%). Fifty-two per cent of patients were operated on during the first year after diagnosis (median size: 40 mm (2-200)), 9% had resection beyond 1 year of follow-up (3 years (1-20), size at diagnosis: 25 mm (4-140)) and 39% had no surgery (3.6 years (1-23), 25.5 mm (1-200)). Surgical indications were (not exclusive) uncertain diagnosis (60%), symptoms (23%), size increase (12%), large size (6%) and adjacent organ compression (5%). In patients followed beyond 1 year (n=1271), size increased in 37% (growth rate: 4 mm/year), was stable in 57% and decreased in 6%. Three serous cystadenocarcinomas were recorded. Postoperative mortality was 0.6% (n=10), and SCNs related mortality was 0.1% (n=1). ...
Serous cystadenomas are a type of cystic neoplasm of the pancreas. These lesions are more frequent in those greater than age 70 and are more common in women. They are commonly quite large at the time of diagnosis measuring on average 5-8cm. Even though they are large they almost never cause jaundice and uncommonly will block the pancreatic duct. Thus, they are usually asymptomatic and are most usually found on diagnostic imaging performed for other reasons.. ...
... is ordered to monitor pancreatic, liver, gastrointestinal, and colorectal malignancies.
Yeast, Stem Cells, Cobalt, Asparagine, Glutamine, Patients, Neoplasms, Pancreas, Biomarkers, Cyst, Mutations, Tumor, and Mutation
TY - JOUR. T1 - Primary pancreatic cystic neoplasms revisited. Part I. T2 - Serous cystic neoplasms. AU - Sakorafas, George H.. AU - Smyrniotis, Vasileios. AU - Reid-Lombardo, Kaye M.. AU - Sarr, Michael G.. PY - 2011/6. Y1 - 2011/6. N2 - Primary pancreatic cystic neoplasms have been recognized increasingly during the two recent decades and include mainly serous cystic neoplasms, mucinous cystic neoplasms, and intraductal papillary mucinous neoplasms. Serous cystic neoplasms represent about 30% of all cystic neoplasms of the pancreas and are characterized by their microcystic appearance (on imaging, macroscopically, and microscopically) and their benign biologic behavior. Modern diagnostic methodology allows the preoperative diagnosis with an acceptable accuracy. Currently, indications for resection of serous cystic neoplasms of the pancreas include the presence of symptoms, size , 4 cm (because these large neoplasms have a more rapid growth rate and probably will soon become symptomatic), and ...
The only method you can actually tell how big an ovarian cyst is by going into your physician for an ultrasound. However, kids arent spared of Dermoid cysts - often children get them near to the eyebrows spectrum of ankle aspect and so they feel like rubberized. Many different steps are there in treating Ovarian cyst patients in respect to their person condition. Mucinous cystadenocarcinoma is usually unilateral and involve the existence of irregular dense septa or solid papillary projections which can be usually recognized within cysts ( Fig.. There are generally only a couple of options for treatment; one is surgical removal of the cysts, and the additional is body hormone treatment by means of birth control supplements. She was told the fact that ultrasound search within will be repeated in a few a few months time; in the event the cysts develop larger, they need to be eliminated by medical procedures.. However , a functional cyst may interrupt your menstrual cycle simply by preventing ...
The TP53 gene mutation frequency in ovarian serous carcinomas has been reported to range between 50% and 80%. A research team working at the The Sidney Kimmel Comprehensive Cancer Center of The Johns Hopkins Medical Institutions (Johns Hopkins) made several important findings regarding TP53 gene mutations with respect to high grade ovarian serous carcinoma, as reported in the International Journal of Gynecological Cancer. Ovarian serous carcinoma is the most common tumor subtype within the epithelial ovarian cancer histological classification.. According to the Johns Hopkins research team, a stringent analysis of the TP53 gene using purified epithelial tumor samples has not been performed to accurately assess the TP53 gene mutation frequency and its correlation to tumor histologic grade. The research team assessed the TP53 gene mutational profile in a relatively large series of high-grade (53 primary tumors and 18 recurrent tumors) and 13 low-grade ovarian serous tumors. All samples were ...
DISEASE CHARACTERISTICS: Histologically confirmed ductal or undifferentiated primary pancreatic cancer for which no standard curative therapy exists Progressive locally advanced disease after combined chemotherapy and radiotherapy OR Not a candidate for combined therapy OR Metastatic disease No islet cell, acinar cell, or cystadenocarcinomas Measurable or evaluable disease No known brain metastases. PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Karnofsky 50-100% Life expectancy: Not specified Hematopoietic: WBC at least 3,500/mm3 Absolute neutrophil count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than upper limit of normal (ULN) SGOT no greater than 2.5 times ULN Renal: Creatinine no greater than ULN OR Creatinine clearance at least 60 mL/min Cardiovascular: No symptomatic congestive heart failure No unstable angina No cardiac arrhythmia Other: No other uncontrolled illness No active infection No allergy to platinum compounds, ...
Benign serous tumours are loculated, have one layer of flattened or cuboidal epithelium as well as the absence of mitoses. Papillae are occasionally present about the exterior or interior surfaces. Samples of serous cystadenomas can be found at ...
Risk of Malignancy in Unilocular Ovarian Cystic Tumors Less Than 10 Centimeters in Diameter Susan C. Modesitt, MD, Edward J. Pavlik, PhD, Frederick R. Ueland, MD, Paul D. DePriest, MD, R. J. Kryscio, PhD,
Darshak Shah, MD, MBBS, Ashish Padnani, MD, MBBS, Gaurav Sharma, MD, MBBS, Litong Du, MD, Saurabh Sharma, MD, MBBS. New York Hospital Queens, New York.. Background:. Appendiceal Mucocele is a very rare disease and found in only 0.3-0.4% appendectomies. It is characterized by mucoid accumulation in theappendix lumen and can present with diverse clinical features or just as an asymptomatic mass. It can be distinguished based on pathology as simple appendiceal mucocele, mucocele with epithelial hyperplasia, cystadenoma and cystadenocarcinoma. the last two are classified as neoplastic forms ...
A 53-yr-old woman with a history of hepatic cystadenoma 25 yr before presented with a simple hepatic cyst, which evolved over 9 yr into a complex cystadenoma with septations and internal bleeding. She was treated with a left hepatectomy. Review of the literature shows that hepatic cystadenomas, although rare, frequently can recur years later and have potential for malignant transformation. Histologic similarities of one variant with ovarian stroma raises interesting possibilities regarding the origin of these lesions. The best treatment results are obtained with radical excision ...
Certificates of Analysis are associated not only with a product, but also with a specific lot of that product. For a given product, there may be several Certificates of Analysis, especially if it is an older product line and has had several lots produced over the years. Using the Certificate of Analysis search tool, you can enter the catalog number and lot/control number for the specific product you have on hand and download the exact Certificate of Analysis you need.. ...
Decreased Expression of 14-3-3,i,σ,/i, Is Predictive of Poor Prognosis for Patients with Human Uterine Papillary Serous Carcinoma (2013 ...
Compagno J, Oertel JE. Microcystic adenomas of the pancreas (glycogen-rich cystadenomas): a clinicopathologic study of 34 cases. Am J Clin Pathol. 1978 Mar; 69(3):289-98.. ...
TY - JOUR. T1 - Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors. T2 - A novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems. AU - Wang, Jun. AU - Lin, Lynne. AU - Parkash, Vinita. AU - Schwartz, Peter E.. AU - Lauchlan, Stuart C.. AU - Zheng, Wenxin. PY - 2003/1/20. Y1 - 2003/1/20. N2 - The role of FSHR expression in ovarian cancer development is not clear. We examined quantitative expression of FSHR in different types of OET, presumed precursor lesions and peritoneal implants and further discussed FSH as a key growth-promotion factor for the process of ovarian epithelial tumorigenesis. Thirty-five primary OET specimens, including 5 serous cystadenomas, 4 papillary serous cystadenomas, 9 SBTs and 17 serous carcinomas, were examined for quantitative FSHR expression. Ten paired samples (3 benign cystadenomas, 5 SBTs and 2 carcinomas) were obtained from several morphologically different areas, including ...
Eighty five ovarian epithelial and non-epithelial tumours were studied by peroxidase histochemical staining for their reactivity with six monoclonal human milk fat globule (HMFG) antibodies, peanut agglutinin (PNA) lectin, and a monoclonal cytokeratin antibody. HMFG IIIC12 and cytokeratin antibodies distinguished epithelial from non-epithelial tumours. The staining patterns of mucinous and serous tumours were essentially different from each other; poorly differentiated anaplastic carcinomas showed similar antigenic content to that of the serous cystadenocarcinomas. Furthermore, staining with PNA lectin and HMFG antibodies was useful in distinguishing clear cell carcinomas from other malignant epithelial tumours of the ovary.. ...
The effective treatment of ovarian serous carcinoma remains a major challenge because of the recurrence of platinum-resistant tumors. The mechanism of platinum-resistance may involve decreased cellular uptake caused by abnormalities of transporters, intracellular cisplatin inactivation (e.g., caused by glutathione), and increased DNA repair (18). However, no available therapy prevents platinum-resistance.. TBX2 is overexpressed by numerous human cancers (7-14). TBX2 may serve as a prognostic factor of breast cancer (7,9), melanoma (8), gastric cancer (10), prostate cancer (11), laryngeal squamous cell carcinoma (12), and non-small cell lung cancer (14). TBX2 is associated with resistance to therapeutic drugs such as cisplatin and doxorubicin (15,16), and TBX2 therefore may serve as a therapeutic target.. One report shows that chromosome 17q12-q24 harbors strong candidates for ovarian tumorigenesis, such as LASP1 (17q12), TGF11 (17q21.32), MUL (17q23.2), TBX2 (17q23.2), AXIN2 (17q24.3), and GRB2 ...
People with a hereditary risk of developing pancreatic cancer have the highest risk of developing pancreatic lesions before they experience symptoms of pancreatic cancer, according to Johns Hopkins...
Borderline Ovarian Clear Cell Tumor Borderline Ovarian Serous Tumor Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Cervical Small Cell Carcinoma Cervical Squamous Cell Carcinoma, Not Otherwise Specified Childhood Embryonal Rhabdomyosarcoma Childhood Malignant Ovarian Germ Cell Tumor Endometrioid Stromal Sarcoma Gestational Trophoblastic Tumor Malignant Mesothelioma Malignant Ovarian Epithelial Tumor Melanoma Neoplasm of Uncertain Malignant Potential Ovarian Brenner Tumor Ovarian Clear Cell Cystadenocarcinoma Ovarian Serous Cystadenocarcinoma Paget Disease of the Vulva Recurrent Cervical Carcinoma Recurrent Fallopian Tube Carcinoma Recurrent Ovarian Carcinoma Recurrent Ovarian Germ Cell Tumor Recurrent Primary Peritoneal Carcinoma Recurrent Uterine Corpus Carcinoma Recurrent Vaginal Carcinoma Recurrent Vulvar Carcinoma Stage I Ovarian Cancer Stage I Uterine Corpus Cancer Stage I Vaginal Cancer Stage I Vulvar Cancer Stage IA Cervical Cancer Stage IA Fallopian Tube Cancer Stage IA Ovarian ...
Logical Images, Inc. d/b/a VisualDx (hereinafter "VisualDx", "we", "us", or "our") has created this Acceptable Use Policy, Medical Disclaimer, & Copyright Notice (this "Notice") to inform you (hereinafter "you", "your", or "yourself") as a purchaser of a license for and/or user of the software hosted by VisualDx known as VisualDx (the "Software") of certain important terms and conditions set forth in the VisualDx End User License Agreement that governs your license for and/or use of the Software (the "EULA"). This Notice is subject to all of the terms and conditions set forth in the EULA and does not replace or limit it in anyway. You should read the EULA in detail prior to purchasing a license for or using the Software to make sure you understand and agree to its terms and conditions. Nothing in this Notice will (a) expand your rights or VisualDx′s obligations under the EULA or (b) modify or otherwise affect any terms and conditions of the EULA or the rights of the parties under the EULA. In ...
Mucinous cystadenoma is a type of tumor that usually develops in the ovaries, pancreas, or appendix. Its typically benign, but...
I had always assumed that hidradenoma papilliferum (HP), which characteristically appears in the vulvar region, was derived from apocrine glands. Until I read the article by El-Khoury et al (1) I had never even heard of mammary-like anogenital glands (MLAGs).
Causes of ovarian serous cystadenoma - What causes an ovarian serous cystadenoma to rupture do I need surgery if rupture? Pressure. The increased pressure and weak wall of the ovary can cause it to rupture - you do not need surgery if it does. You might consider getting it removed before it does though.
Robot-Assisted Laparoscopic Vesiculectomy for Large Seminal Vesicle Cystadenoma: A Case Report and Review of the Literature. ( 25862321 ) ...
Evaluation and measurement of burden of disease in ovarian cancer has always been a challenge. Due to its characteristics, it is difficult to identify response or recurrence in imaging studies. Historically, CA125 is the most important biomarker for follow-up in ovarian cancer [11-13]. It has a direct relationship with burden of disease, and has been used to evaluate treatment response and recurrence.. A high baseline level of CA125 is often associated with worst outcomes for primary treatment [14], even in patients with cancer of low malignant potential [15]. Similarly, a high level of CA125 often demonstrates a massive recurrence. Additionally, CA125 decrements are useful for determining effectiveness of therapy in the neoadjuvant setting and can predict optimal cytorreduction and better outcome [16].. Much is being done at improvement in the quality of CA125 as a biomarker. Nevertheless, concrete data is lacking to allow the physician to rely only on its levels to make definite decisions, ...
美国,旧金山,洛杉矶,纽约,生活,华人,中文,百科知识,移民,租房,买房,保险,汽车,招聘,求职,求助,租车,保姆,月嫂,家政,用工
Note: Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. SEER registries are not required to collect these cases for diagnoses made 1/1/2001 and after. However, cases diagnosed prior to 1/1/2001 should still be abstracted and reported to SEER. ...
Note: Borderline cystadenomas M-8442, 8451, 8462, 8472, 8473, of the ovaries moved from behavior /3 (malignant) to /1 (borderline malignancy) in ICD-O-3. SEER registries are not required to collect these cases for diagnoses made 1/1/2001 and after. However, cases diagnosed prior to 1/1/2001 should still be abstracted and reported to SEER. ...
A cystic tumor of the ovary either nonneoplastic (follicle, lutein, germinal inclusion, or endometrial) or neoplastic; either benign (pseudomucinous or serous cystadenoma, or dermid) or malignant (carcinoma ...
Cystic mass in the pancreatic head that proved to be an adenocarcinoma in a patient who also has a metastasized ovarian adenocarcinoma that ...
Background Information: Mature cystic teratomas (MCTs) and serous cystadenomas are the two most common ovarian neoplasms encountered in clinical practice. Majority of ovarian masses encountered in clinical practice is benign. Approximately 15-25% of ovarian neoplasms are MCTs, also known as dermoids. Ultrasound (US) is often the first imaging test in the diagnosis of an ovarian mass across all ages. In the United States, there is a propensity for follow-up MRI and CT when an ovarian mass is encountered by US. US has multiple desirable attributes, which include wide availability, relatively quick procedure, no peripheral IV catheter placement for iodinated or gadolinium contrast injection, lack of ionizing radiation, and relatively low cost. The purpose of this exhibit is to review the sonographic features of MCTs with correlation to CT and MRI, as well as correlation to the various components of the three germ layers found in ovarian MCTs ...
Cystic tumors of the pancreas today are diagnosed more frequently in clinical practice, mainly due to an increased use of the modern advanced imaging modalities.. Bland cysts of the pancreas most often develop after chronic or acute inflammation of the pancreas. However, the current knowledge concerning the development of cystic neoplasias of the pancreas is still rudimentary.. Histopathologically, 90% of pancreatic cystic neoplasias are represented by four types: serous microcystic (SCN), mucinous cystic (MCN), intraductal papillary mucinous (IPMN) and solid pseudopapillary (SPN) neoplasias. Surgical treatment of these lesions can be highly challenging and occasionally demands complex surgical approaches that should be put in the hands of skilled pancreatic surgeons in experienced high-volume centers.. While some of the described cystic tumors are harmless, such as SCNs of the pancreas, others such as IPMN and MCN harbor relevant malignant potential. The differential diagnosis of these lesions ...
I guess my hamster days steroid high is over, because I slept 10 hours last night and woke up with something similar to what Marge described, a sort of fogginess. Its not bad, but I feel like if I crawled back under the covers, I just might go back to sleep again. (Not doing that!) I agree that we are all doing so much better than any of us probably dared to hope. There are surely some rough days ahead, but one day at a time is the way to go, and making the most of each good day. I wonder if we will continue to come here after our treatments are over??? I see 20-year survivors posting here on other boards, wanting to be here as a resource to those that come after them with their same cancers. Id like to think well be like that, with this thread always flagged for email alerts, ready to jump back in when those newly diagnosed with UPSC using the SEARCH box, find this thread. Even if any of us decide to close the door on this chapter of our life and never look back, think how great it will ...
Journal of Clinical and Diagnostic Research aims to publish findings of doctors at grass root level and post graduate students, so that all unique medical experiences are recorded in literature.
Anne Marie Lennon, MD, PhD, director of the Pancreatic Cyst Clinic discusses the prevalence and optimal management of pancreatic cysts.
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
Ovarian cancer is a cancer that forms in an ovary. It results in abnormal cells that have the ability to invade or spread to other parts of the body. SK-OV-3, NIH:OVCAR-3 and HO-8910 are the ovarian carcinoma cell lines derived from human ovarian tumor. Studies were carried out to determin
Elishaev E, Gilks CB, Miller D, Srodon M, Kurman RJ, Ronnett BM. Synchronous and metachronous endocervical and ovarian neoplasms: evidence supporting interpretation of the ovarian neoplasms as metastatic endocervical adenocarcinomas simulating primary ovarian surface epithelial neoplasms. Am J Surg Pathol. 2005 Mar;29(3):281-94 ...
When it comes to pancreatic cysts, expert evaluation is vital to accurately diagnose the nature of the cyst, and then determine the best course of treatment.
Not all neoplasms represent cancer, and some have overlapping sonographic characteristics. Heres what you need to know to differentiate what is benign from what is malignant.
The inclusion criteria were as follows: age between 15 years old and more than 60 years old at the time of the initial diagnosis, all stages of ovarian neoplasms, and receiving only surgical treatment.
췌장과 비장 내 낭성 병변은 방사선학적 영상검사로 진단이 비교적 쉬운 편이나, 췌장 내 부비장에서 발생한 유표피 낭종은 특이적 방사선 소견이 없어 진단하기 매우 어려워 췌장 내 낭성 종양으로 오진되기가 쉽다. 췌장 내 부비장 조직이 상대적으로 많다면, 종괴의 고형 성분이 복부 전산화 단층촬영 검사에서 비장과 비슷한 조영증강을 보이고 자기공명영상 검사에서 비장과 같은 신호 변화를 보인다는 점에서 방사선학적 영상검사로 췌장 내 부비장의 유표피 낭종을 진단 할 수 있다. 하지만 부비장 조직이 많지 않으면 정확한 진단은 매우 힘들며 본 증례에서도 수술 후 절제 조직에서 부비장 조직이 상대적으로 적게 관찰되었으며 이로 인해서 수술 전 영상검사로 정확한 진단은 할 수 없었다. 췌장 내 낭종이 있을 경우 감별진단을 해야 하는 질환으로 ...
Researchers used Caris Molecular Intelligence® to evaluate 240 uterine papillary serous carcinoma (UPSC) and 1,587 epithelial ovarian serous carcinoma (EOC-S) samples, and to compare the molecular profiles of the two cancer subtypes.. The tumor suppressor gene TP53 was the most commonly mutated gene in both UPSC and EOC-S (76% vs. 69%) samples. UPSCs were more likely than EOC-S samples to harbor mutations in the oncogenes PIK3CA (29% vs. 2%), FBXW7 (12% vs. 1%), KRAS (9% vs. 5%), the tumor suppressor protein PTEN (7% vs. 1%), and CTNNB1 (2% vs. 0%).. "Whereas uterine papillary serous carcinoma appears to have a distinct mutation profile, indicating higher activity of the PI3K/PTEN/mTOR pathway, we saw no differences between uterine papillary and ovarian serous carcinomas in alteration of the homologous recombination pathway," remarked principal investigator Robert DeBernardo, MD, Gynecologic Oncologist and Director of Minimally Invasive Surgery at the Cleveland Clinic Ob/Gyn & Womens Health ...
41. Lilium papilliferum Franchet, J. Bot. (Morot). 6: 316. 1892. 乳头百合 ru tou bai he Bulb ovoid, ca. 2.5 cm in diam.; scales white, ovate or lanceolate-ovate. Stem to 60 cm, tinged purple, densely papillose. Leaves scattered, mostly in middle and distal parts of stem, linear, 5.5--7 cm × 2--4 mm. Flowers several (usually 5) in a raceme, nodding, fragrant. Tepals purple-red or reddish brown, unspotted, oblong, slightly narrowed basally, 3.5--3.8 × 1--1.3 cm; nectaries papillose and with cristate projections on both surfaces. Filaments ca. 2 cm, glabrous; anthers light brown, with orange pollen. Ovary cylindric, ca. 1 cm × 4 mm. Style ca. 1.3 cm. Capsule oblong, 2--2.5 × 1.5--2 cm. Fl. Jul, fr. Sep.. * Bushy slopes; 1000--1300 m. Shaanxi, Sichuan, Yunnan.. ...
Serous borderline tumor (SBT) of the micropapillary type (SBT-MP) became one of the major pathological SBT diagnoses in addition to typical SBT, and was also defined as
Purpose: Pancreatic cysts are common and pose diagnostic and management challenges. Pancreatic cyst fluid markers have the potential to aid in the management of cysts with concerning imaging findings. Our aim was to evaluate cyst fluid methylated DNA markers for their accuracy for predicting the histologic grade of neoplastic pancreatic cysts. Experimental Design: Pancreatic cyst fluid samples from 183 patients (29 discovery, 154 validation) aspirated after surgical resection were analyzed for methylated DNA at selected genes (SOX17, BNIP3, FOXE1, PTCHD2, SLIT2, EYA4 and SFRP1) using methylation-specific droplet-digital PCR (dd-QMSP). Methylated DNA levels were evaluated for their accuracy at predicting the grade of dysplasia of the pancreatic cyst. Results: All six markers evaluated in the validation set could accurately distinguish high-risk cystic neoplasms (with high-grade dysplasia and/or associated invasive cancer) from low-risk cysts (lower grades of dysplasia) with accuracies from 79.8 ...
Bouchalova, P., Nenutil, R., Muller, P., Hrstka, R., Appleyard, M. V., Murray, K., Jordan, L. B., Purdie, C. A., Quinlan, P., Thompson, A. M., Vojtesek, B. & Coates, P. J. Jul 2014 In : Journal of Pathology. 233, 3, p. 238-246 9 p.. Research output: Contribution to journal › Article ...
Please help as i am so worried and would like to here some honest advice. My 11 year old started her periods six months ago, and 2 weeks ago was admitted to hospital with abdominal pain and feeling si...
What is Intermittent Fasting? Contrary to popular belief, intermittent fasting (IF) is actually an eating pattern. Believe it or not, you can have a healthy

Mucinous cystadenocarcinoma - WikipediaMucinous cystadenocarcinoma - Wikipedia

Mucinous cystadenocarcinoma is a type of tumor in the cystadenocarcinoma grouping. It can occur in the breast as well as in the ... Honma N, Sakamoto G, Ikenaga M, Kuroiwa K, Younes M, Takubo K (August 2003). "Mucinous cystadenocarcinoma of the breast: a case ... http://radiopaedia.org/articles/mucinous-cystadenocarcinoma-of-ovary. ...
more infohttps://en.wikipedia.org/wiki/Mucinous_cystadenocarcinoma

The long-term survival in primary retroperitoneal mucinous cystadenocarcinoma: a case report | Surgical Case Reports | Full TextThe long-term survival in primary retroperitoneal mucinous cystadenocarcinoma: a case report | Surgical Case Reports | Full Text

RetroperitonealCystadenocarcinomaMucinous. Background. Primary retroperitoneal mucinous cystadenocarcinoma (PRMC) is extremely ... Primary retroperitoneal mucinous cystadenocarcinoma in a male patient: a case report. Cases J. 2009;2:7196.View ArticlePubMed ... Mucinous cystadenocarcinoma of the retroperitoneum: report of a case. Surg Today. 2001;31:747-50.View ArticlePubMedGoogle ... Primary retroperitoneal mucinous cystadenocarcinoma: report of two cases. World J Surg Oncol. 2007;5:5.View ArticlePubMedPubMed ...
more infohttps://surgicalcasereports.springeropen.com/articles/10.1186/s40792-017-0394-z

Ovarian granulosa cell tumor - Answers on HealthTapOvarian granulosa cell tumor - Answers on HealthTap

Doctors give trusted, helpful answers on causes, diagnosis, symptoms, treatment, and more: Dr. Hashemi on ovarian granulosa cell tumor: Sperm in men (&testosterone) and eggs/ova in women (& estrogens), and these are also the sites of germ cell tumors. Outside the gonads, the mediastinum and brain (pineal) are the most common extragonadal sites. These are known to produce markers (hcg, alphafeto-protein) and responsve and curable with chemotherapy. Hope this helps.
more infohttps://www.healthtap.com/topics/ovarian-granulosa-cell-tumor

Cystadenocarcinoma - WikipediaCystadenocarcinoma - Wikipedia

Cystadenocarcinoma is a malignant form of a cystadenoma and is a malignant neoplasm derived from glandular epithelium, in which ... Papillary serous cystadenocarcinoma "Female Genital Pathology". Retrieved 2009-03-23. King JC, Ng TT, White SC, Cortina G, ... Reber HA, Hines OJ (October 2009). "Pancreatic serous cystadenocarcinoma: a case report and review of the literature". J ...
more infohttps://en.wikipedia.org/wiki/Cystadenocarcinoma

Mucinous Cystadenocarcinoma, Appendix | SpringerLinkMucinous Cystadenocarcinoma, Appendix | SpringerLink

However, the distinction between a cystic carcinoma (i.e., cystadenocarcinoma) and one that is not cystic has not been shown to ... The term "mucinous cystadenocarcinoma" may be used for well-differentiated mucinous adenocarcinomas with cystic structures. ... Svrcek M. (2017) Mucinous Cystadenocarcinoma, Appendix. In: Carneiro F., Chaves P., Ensari A. (eds) Pathology of the ...
more infohttps://link.springer.com/referenceworkentry/10.1007/978-3-319-40560-5_1512

papillary cystadenocarcinomapapillary cystadenocarcinoma

serous cystadenocarcinoma*adenocarcinoma*cystadenocarcinoma*survival rate*ovarian neoplasms*neoplasm staging*uterine neoplasms* ... Cystadenocarcinoma (papillary cystadenocarcinoma) of the salivary gland is a rare malignant neoplasm... ... Cystadenocarcinoma (papillary cystadenocarcinoma) of the submandibular gland. A Harimaya. Department of Otolaryngology, Sapporo ... Cystadenocarcinoma (papillary cystadenocarcinoma) of the submandibular gland. A Harimaya. Department of Otolaryngology, Sapporo ...
more infohttps://www.labome.org/topics/diseases/neoplasms/neoplasms/glandular/and/cystadenocarcinoma/papillary-cystadenocarcinoma-5739.html

Biliary Cystadenoma/Cystadenocarcinoma Imaging: Overview, Radiography, Computed TomographyBiliary Cystadenoma/Cystadenocarcinoma Imaging: Overview, Radiography, Computed Tomography

encoded search term (Biliary Cystadenoma/Cystadenocarcinoma Imaging) and Biliary Cystadenoma/Cystadenocarcinoma Imaging What to ... Biliary Cystadenoma/Cystadenocarcinoma Imaging. Updated: Nov 28, 2015 * Author: Mohammad Alobaidi, MD; Chief Editor: John ... Biliary cystadenoma and cystadenocarcinoma: CT and sonographic findings. AJR Am J Roentgenol. 1989 Sep. 153(3):507-11. [Medline ... Koroglu M, Akhan O, Akpinar E, Oto A, Gumus B. Biliary cystadenoma and cystadenocarcinoma: two rare cystic liver lesions. JBR- ...
more infohttps://emedicine.medscape.com/article/364156-overview

Pathology Outlines - CystadenocarcinomaPathology Outlines - Cystadenocarcinoma

2005 WHO classification considered low grade salivary duct carcinoma to be a variant of cystadenocarcinoma, designated as low ... Also called papillary cystadenocarcinoma, mucus producing adenopapillary (nonepidermoid) carcinoma, malignant papillary ... Cite this page: Fernandez NC Cystadenocarcinoma. PathologyOutlines.com website. http://www.pathologyoutlines.com/topic/ ...
more infohttp://www.pathologyoutlines.com/topic/oralcavitycystadenocarcinoma.html

Atypical breast cyst: adenocarcinoma | Radiology Case | Radiopaedia.orgAtypical breast cyst: adenocarcinoma | Radiology Case | Radiopaedia.org

From the case: Atypical breast cyst: adenocarcinoma Ultrasound Loading Stack - 0 images remaining ...
more infohttps://radiopaedia.org/cases/atypical-breast-cyst-adenocarcinoma

An extremely rare cause of acute abdomen in pregnancy: ruptured pancreatic mucinous cystadenocarcinoma.An extremely rare cause of acute abdomen in pregnancy: ruptured pancreatic mucinous cystadenocarcinoma.

To our knowledge, there have been 2 published cases of pancreatic mucinous cystadenocarcinoma (PMC) during pregnancy in the ... Pancreatic cystadenocarcinoma is an extremely rare neoplasm in pregnancy. ... Previous Document: Mucinous cystadenocarcinoma of the pancreas during pregnancy.. Next Document: Triterpenoids and rexinoids as ... Pancreatic cystadenocarcinoma is an extremely rare neoplasm in pregnancy. To our knowledge, there have been 2 published cases ...
more infohttp://www.biomedsearch.com/nih/extremely-rare-cause-acute-abdomen/17446849.html

Metastatic, papillary cystadenocarcinoma of the mammary gland in a black-footed ferretMetastatic, papillary cystadenocarcinoma of the mammary gland in a black-footed ferret

... Journal of Wildlife Diseases By:. J.W. ... Metastatic, papillary cystadenocarcinoma of the mammary gland in a black-footed ferret. Series title:. Journal of Wildlife ...
more infohttps://pubs.er.usgs.gov/publication/5221624

Search of: methodist hospital | Recruiting, Not yet recruiting, Available Studies | Cystadenocarcinoma | Houston - List...Search of: 'methodist hospital' | Recruiting, Not yet recruiting, Available Studies | 'Cystadenocarcinoma' | Houston - List...

methodist hospital , Cystadenocarcinoma , Houston (25 studies) * methodist hospital , Recruiting, Not yet recruiting, ... methodist hospital , Recruiting, Not yet recruiting, Available Studies , Cystadenocarcinoma , Houston. Need help? See RSS ... 5 Studies found for: methodist hospital , Recruiting, Not yet recruiting, Available Studies , Cystadenocarcinoma , Houston ... Recruiting, Not yet recruiting, Available Studies , Cystadenocarcinoma , Houston (5 studies) * ...
more infohttps://clinicaltrials.gov/ct2/results?term=%22methodist+hospital%22&recr=Open&cond=%22Cystadenocarcinoma%22&state1=NA%3AUS%3ATX&locn=Houston

Proliferative Brenner Tumor with Borderline Mucinous Cystadenocarcinoma of the Ovary in a 75-Year-Old WomanProliferative Brenner Tumor with Borderline Mucinous Cystadenocarcinoma of the Ovary in a 75-Year-Old Woman

Histopathological examination revealed proliferative Brenner ovarian tumor with borderline mucinous cystadenocarcinoma, and ... We report here an extremely rare case of proliferative Brenner tumor with borderline mucinous cystadenocarcinoma of the ovary, ... We report here an extremely rare case of proliferative Brenner tumor with borderline mucinous cystadenocarcinoma of the ovary, ... Proliferative Brenner Tumor with Borderline Mucinous Cystadenocarcinoma of the Ovary in a 75-Year-Old Woman ...
more infohttps://www.scirp.org/journal/PaperInformation.aspx?PaperID=45118

Gene Set - cystadenocarcinomaGene Set - cystadenocarcinoma

cystadenocarcinoma Gene Set. Dataset. DISEASES Text-mining Gene-Disease Assocation Evidence Scores ... 273 genes co-occuring with the disease cystadenocarcinoma in abstracts of biomedical publications from the DISEASES Text-mining ...
more infohttps://amp.pharm.mssm.edu/Harmonizome/gene_set/cystadenocarcinoma/DISEASES+Text-mining+Gene-Disease+Assocation+Evidence+Scores

Osteopathic Approach to the Diagnosis of Appendiceal Mucinous Cystadenocarcinoma Mimicking Primary Ovarian Malignant Neoplasm |...Osteopathic Approach to the Diagnosis of Appendiceal Mucinous Cystadenocarcinoma Mimicking Primary Ovarian Malignant Neoplasm |...

Osteopathic Approach to the Diagnosis of Appendiceal Mucinous Cystadenocarcinoma Mimicking Primary Ovarian Malignant Neoplasm. ... Osteopathic Approach to the Diagnosis of Appendiceal Mucinous Cystadenocarcinoma Mimicking Primary Ovarian Malignant Neoplasm ... Osteopathic Approach to the Diagnosis of Appendiceal Mucinous Cystadenocarcinoma Mimicking Primary Ovarian Malignant Neoplasm ... All of the findings together were consistent with primary PMP from a mucinous cystadenocarcinoma, with the appendix as the ...
more infohttp://jaoa.org/article.aspx?articleid=2531569

Cystadenocarcinoma | CTDCystadenocarcinoma | CTD

Cystadenocarcinoma 2.. Diseases ← Neoplasms ← Neoplasms by Histologic Type ← Neoplasms, Glandular and Epithelial ← Neoplasms, ...
more infohttp://ctdbase.org/detail.go?type=disease&acc=MESH%3AD003536

Primary mucinous cystadenocarcinoma of the renal pelvis misdiagnosed as ureteropelvic junction stenosis with renal pelvis stone...Primary mucinous cystadenocarcinoma of the renal pelvis misdiagnosed as ureteropelvic junction stenosis with renal pelvis stone...

Primary mucinous cystadenocarcinoma of the renal pelvis misdiagnosed as ureteropelvic junction stenosis with renal pelvis stone ... Mucinous cystadenocarcinoma of the renal pelvis: a case report and clues to histogenesis. Bmj Case Reports 2009: -, 2009 ... Primary mucinous cystadenocarcinoma of renal pelvis: a case report. Cases Journal 2(): 9395-9395, 2010 ... Primary mucinous cystadenocarcinoma of the renal pelvis misdiagnosed as ureteropelvic junction stenosis with renal pelvis stone ...
more infohttps://eurekamag.com/research/058/625/058625394.php

Cytomorphologic features of papillary cystadenocarcinoma of the parotid. | DocphinCytomorphologic features of papillary cystadenocarcinoma of the parotid. | Docphin

Cytomorphologic features of papillary cystadenocarcinoma of the parotid. , Diagnostic cytopathology , 6/1/2002 ... Cytomorphologic features of papillary cystadenocarcinoma of the parotid. Kusum Kapila Kusum Verma 6/1/2002 ... Kapila K, Verma K. Cytomorphologic features of papillary cystadenocarcinoma of the parotid. Diagn Cytopathol. 2002;26(6):392-7. ... The fine-needle aspiration cytology findings in four cases of recently classified cystadenocarcinoma of the parotid gland are ...
more infohttps://www.docphin.com/research/article-detail/8694831/PubMedID-12112832/Cytomorphologic-features-of-papillary-cystadenocarcinoma-of-the-parotid

Bile Duct Cystadenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical TrialsBile Duct Cystadenocarcinoma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MalaCards integrated aliases for Bile Duct Cystadenocarcinoma:. Name: Bile Duct Cystadenocarcinoma 12 15 74 ... MalaCards based summary : Bile Duct Cystadenocarcinoma, also known as biliary cystadenocarcinoma, is related to sclerosing ... MalaCards organs/tissues related to Bile Duct Cystadenocarcinoma:. 42 Liver, Breast, Testis, Lung, Ovary, Pancreas, Thymus ... cystadenocarcinoma 30.5. CEACAM5 KRT7 MUC1 4. polycystic liver disease 1 with or without kidney cysts 29.3. CALB2 CEACAM5 KRT20 ...
more infohttps://www.malacards.org/card/bile_duct_cystadenocarcinoma

Biliary cystadenocarcinoma | Radiology Reference Article | Radiopaedia.orgBiliary cystadenocarcinoma | Radiology Reference Article | Radiopaedia.org

Biliary cystadenocarcinoma: a case report disease]. J Radiol. 2005;86 (9 Pt 1): 1035-7. J Radiol (link) - Pubmed citation. ... Biliary cystadenocarcinoma of the liver: the need for complete resection. Eur. J. Cancer. 1998;34 (12): 1845-51. Eur. J. Cancer ... Biliary cystadenoma and cystadenocarcinoma: CT and sonographic findings. AJR Am J Roentgenol. 1989;153 (3): 507-11. AJR Am J ... Intrahepatic biliary cystadenocarcinoma: clinical analysis of 4 cases. HBPD INT. 2009;8 (1): 71-4. HBPD INT (link) - Pubmed ...
more infohttps://prod-images.static.radiopaedia.org/articles/biliary-cystadenocarcinoma?lang=us

Mucinous cystadenoma and cystadenocarcinoma - Herb Kosten FoundationMucinous cystadenoma and cystadenocarcinoma - Herb Kosten Foundation

Mucinous cystadenoma and cystadenocarcinoma. Written by Kosten Foundation on June 8, 2017. . Posted in Definitions, ... Even if a cystadenocarcinoma is found, the prognosis is quite good if the tumor can be surgically removed. ...
more infohttps://www.kostenfoundation.com/mucinous-cystadenoma-and-cystadenocarcinoma/

Atypical breast cyst: adenocarcinoma | Radiology Case | Radiopaedia.orgAtypical breast cyst: adenocarcinoma | Radiology Case | Radiopaedia.org

From the case: Atypical breast cyst: adenocarcinoma Ultrasound Loading Stack - 0 images remaining ...
more infohttps://images.radiopaedia.org/cases/atypical-breast-cyst-adenocarcinoma?lang=us

Videos - Ovarian Histopathology - Serous Cyst Adenocarcinoma | DrugsUpdate IndiaVideos - Ovarian Histopathology - Serous Cyst Adenocarcinoma | DrugsUpdate India

Ovarian Histopathology - Serous Cyst Adenocarcinoma. BACK TO VIDEOS Ovarian Histopathology - Serous Cyst Adenocarcinoma. ...
more infohttp://www.drugsupdate.com/videos/listing/1131

Mucinous cystadenocarcinoma ovary presented as giant pelvic abdominal Mass 
    		
    		
    	Mucinous cystadenocarcinoma ovary presented as giant pelvic abdominal Mass

Mucinous cystadenocarcinoma ovary presented as giant pelvic abdominal Mass Jagtap, Sunil 관련메뉴. Dhawan, Shrutika 관련메뉴. Jagtap, ...
more infohttp://www.ndsl.kr/ndsl/search/detail/article/articleSearchResultDetail.do?cn=NART82058183
  • 273 genes co-occuring with the disease cystadenocarcinoma in abstracts of biomedical publications from the DISEASES Text-mining Gene-Disease Assocation Evidence Scores dataset. (mssm.edu)
  • The fine-needle aspiration cytology findings in four cases of recently classified cystadenocarcinoma of the parotid gland are reported. (docphin.com)